Eric K Nakakura
Overview
Explore the profile of Eric K Nakakura including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
78
Citations
2279
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wang S, Kidder W, Joseph N, Le B, Lindsay S, Moon F, et al.
Endocr Relat Cancer
. 2025 Jan;
32(3).
PMID: 39813097
Grade progression of well-differentiated pancreatic neuroendocrine tumors (panNETs) can occur over time, with G1/2 to G3 being the most clinically relevant form. Here, we conducted a retrospective cohort study of...
2.
Wong P, Pollini T, Adam M, Alseidi A, Corvera C, Hirose K, et al.
Ann Surg Oncol
. 2024 Oct;
32(1):536.
PMID: 39422845
No abstract available.
3.
Hoffman D, Ganjouei A, Hernandez F, Ifuku K, Miller P, Glencer A, et al.
J Gastrointest Surg
. 2024 Aug;
28(11):1799-1804.
PMID: 39181231
Background: Pancreatic cancer is the third leading cause of cancer-related death in the United States, with surgical resection being the only option for long-term survival. The ability to manage vascular...
4.
Wong P, Pollini T, Adam M, Alseidi A, Corvera C, Hirose K, et al.
Ann Surg Oncol
. 2024 Jul;
31(12):8276-8286.
PMID: 39068306
Background: Surgical and adjuvant management of mucinous cystic neoplasms (MCNs) lacks formal guidelines and data is limited to institutional studies. Factors associated with receipt of adjuvant therapy and any associated...
5.
Yogo A, Kasai Y, Nakakura E
J Gastrointest Surg
. 2024 Jul;
28(10):1735-1737.
PMID: 39032553
No abstract available.
6.
Miller P, Nakakura E
Ann Surg Oncol
. 2024 Jun;
31(9):6203-6204.
PMID: 38909112
No abstract available.
7.
Miller P, Romero-Hernandez F, Calthorpe L, Wang J, Kim S, Corvera C, et al.
Ann Surg Oncol
. 2024 Jun;
31(9):6147-6156.
PMID: 38879670
Background: In 2023 alone, it's estimated that over 64,000 patients will be diagnosed with PDAC and more than 50,000 patients will die of the disease. Current guidelines recommend neoadjuvant therapy...
8.
Yogo A, Nakakura E
Ann Surg Oncol
. 2024 May;
31(9):5537-5538.
PMID: 38822170
No abstract available.
9.
Yogo A, Paciorek A, Kasai Y, Moon F, Hirose K, Corvera C, et al.
Ann Surg Oncol
. 2024 May;
31(9):5507-5514.
PMID: 38797790
Background: Ileal neuroendocrine tumors (i-NETs) are characterized by their multifocality and bulky mesenteric mass. Having shown that minimally invasive surgery (MIS) utilizing a hand-access port device has favorable short-term outcomes...
10.
Parikh A, Chee B, Tsai J, Rich T, Price K, Patel S, et al.
Clin Cancer Res
. 2024 May;
30(14):2964-2973.
PMID: 38695832
Purpose: Minimal residual disease (MRD) detection can identify the recurrence in patients with colorectal cancer (CRC) following definitive treatment. We evaluated a plasma-only MRD assay to predict recurrence and survival...